Potential Therapeutic Targets in Uterine Sarcomas

Uterine sarcomas are rare tumors accounting for 3,4% of all uterine cancers. Even after radical hysterectomy, most patients relapse or present with distant metastases. The very limited clinical benefit of adjuvant cytotoxic treatments is reflected by high mortality rates, emphasizing the need for ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuppens, Tine, Tuyaerts, Sandra, Amant, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632006/
https://www.ncbi.nlm.nih.gov/pubmed/26576131
http://dx.doi.org/10.1155/2015/243298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632006/
https://www.ncbi.nlm.nih.gov/pubmed/26576131
http://dx.doi.org/10.1155/2015/243298

Ejemplares similares